The Licensing Deal
Fennec Pharmaceuticals Inc. (FENC) has secured an exclusive licensing deal with Norgine, a key player in the European pharmaceutical landscape. The agreement focuses on the development and commercialization of Pedmark/Pedmarqsi in the EU, Australia, and New Zealand.
Market Approval and Potential
Following FDA approval in 2022, Pedmark became the first and only treatment authorized to reduce cisplatin-induced hearing loss in pediatric patients with localized solid tumors. With existing approval in the UK and EU under the name Pedmarqsi, the drug holds a unique market position.
Financial Implications
Under the terms of the agreement, FENC is set to receive an upfront payment of €40 million from Norgine with potential additional milestone payments totaling up to €210 million. Moreover, FENC stands to gain double-digit royalties on net sales of Pedmarqsi in the licensed territories.
Market Response
Investors responded positively to the news, driving Fennec’s stock price up by 11.4% on March 18. The company’s strategic move to enhance global accessibility to Pedmarqsi and bolster its financial standing were key factors contributing to the market optimism.
Broader Industry Performance
Over the past year, Fennec has outperformed the industry, showcasing a 37% increase in its share value amidst a challenging market environment for medical drug companies.
Future Prospects and Expansion
Fennec remains optimistic about Pedmarqsi’s potential to address the pressing need for mitigating hearing loss in pediatric patients undergoing cisplatin treatment. With plans to seek approvals in additional markets such as Switzerland, Australia, and New Zealand, the company is poised for further expansion.
Stock Recommendations
According to Zacks Research, Fennec currently holds a Zacks Rank #2 (Buy). Other notable stocks in the same industry include ADMA Biologics (ADMA), FibroGen (FGEN), and Adicet Bio, Inc. (ACET). ADMA leads the pack with a Zacks Rank #1 (Strong Buy).
Analyst Insights
The market outlook for ADMA Biologics is promising, with earnings per share estimates seeing a significant upward trend. On the other hand, FibroGen and Adicet Bio, Inc. have faced challenges in their performance, with varying estimates for earnings per share and stock valuation.
